<DOC>
	<DOCNO>NCT02496221</DOCNO>
	<brief_summary>Albiglutide , novel analogue glucagon-like peptide-1 ( GLP-1 ) , develop approve treatment type 2 diabetes mellitus . The primary objective study ass single dose albiglutide affect cholecystokinin-induced gallbladder empty . To make assessment , study participant receive dose albiglutide dose placebo follow cholecystokinin ( CCK ) infusion ultrasound measurement gallbladder . The study comprise two period 20 subject . The screen visit occur within 42 day start Treatment Period 1 . The Treatment Periods separate washout period minimum 42 day . Subjects return follow-up visit 28 day follow last dose albiglutide placebo . The total duration subject 's participation Screening Follow-up approximately 17.5 week . This study post marketing commitment United States Food Drug Administration ( USFDA ) .</brief_summary>
	<brief_title>A Study Evaluating Effect Albiglutide Gallbladder Emptying Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Cholecystokinin</mesh_term>
	<criteria>Between 18 65 year age Healthy Have venous access sufficient allow intravenous ( IV ) infusion blood sample per protocol Subject 's body mass index ( BMI ) &gt; =18 kilogram ( kg ) /meter ( ) ^2 &lt; =30 kg/m^2 Male Female : pregnant ( confirmed test screening timepoints ) , lactate , least one follow condition applies : ) bear child OR b ) agree follow contraception requirement define protocol Capable give sign informed consent Alanine aminotransferase ( ALT ) &gt; 1.5x Upper limit normal ( ULN ) Bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current chronic history liver disease , know hepatic biliary abnormality QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) Systolic blood pressure &gt; =140 millimetre ( mm ) mercury ( Hg ) Screening Diastolic blood pressure &gt; =90 mm Hg Screening Heart rate &gt; 100 beats/min Screening Fasting triglyceride level &gt; 300 milligram/decilitre Screening History cholecystitis gallbladder disease History gallstone , biliary motility dysfunction , condition render subject unsuitable ultrasonography assessment Prior cholecystectomy gallbladder biliary duct procedure , prior ileal gastric surgery , medical procedure preclude gallbladder empty History significant cardiovascular pulmonary dysfunction prior screen History thyroid dysfunction History intestinal obstruction , ileus , lapband , gastrointestinal surgery procedure opinion investigator could influence gastric emptying ( e.g. , gastrectomy , gastric bypass ) History acute chronic pancreatitis History abdominal pain unknown cause History severe gastrointestinal disease , include gastroparesis , inflammatory bowel disease , Crohn 's disease , irritable bowel syndrome Personal family history multiple endocrine neoplasia type 2 Personal family history medullary carcinoma thyroid Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day Current past use medication may significantly affect gastrointestinal and/or gallbladder motility pancreatic hepatobiliary system History regular alcohol consumption within 6 month study Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 3 month prior screen Subject history significant weight loss currently attempt weight loss History sensitivity contraindication study medication component thereof history drug allergy Subject previously receive GLP1 mimetic compound ( e.g. , exenatide , liraglutide , lixisenatide , dulaglutide ) A biliary pathology assess ultrasound An abnormal ( i.e. , outside normal reference range ) thyroid function test assess thyroid stimulate hormone screen An abnormal amylase lipase test screen A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result A positive prestudy drug/alcohol screen A positive test Human immunodeficiency virus ( HIV ) antibody A screening ultrasound demonstrate inadequate image gallbladder , main pancreatic duct , common duct Where participation study would result donation blood blood product excess 500 mL within 56day period The subject participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure 4 new chemical entity within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cholecystokinin</keyword>
	<keyword>ultrasonography</keyword>
	<keyword>Albiglutide</keyword>
	<keyword>Gallbladder ejection fraction</keyword>
</DOC>